Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance of biopharmaceuticals and gene therapies. Spagnol goes on to elaborate on his strategy to revitalize Novasep’s organizational structure and position the company as a reference partner of choice within the biologics space.
Overall, biologics at large are going to be the shapers of the industry moving forward, and I am glad to say our company took this path several years ago
